CHROMIUM ENHANCES INSULIN & GLUT4 ACTION VIA LIPID RAFTS

铬增强胰岛素

基本信息

项目摘要

DESCRIPTION (provided by applicant): Thirty-eight years after the landmark discovery of insulin, chromium was identified to be a separate factor required to maintain normal glucose tolerance. Unlike the intensive research in pursuit of understanding the molecular mechanisms of insulin signaling and resistance to its biological action associated most significantly with obesity and type 2 diabetes, the molecular basis of chromium action has been intermittently studied over the years. Recent data is consistent with the theory that chromium enhances insulin action during the insulin resistant state by amplifying the activity of the insulin receptor. However, given that the etiology of impaired insulin action results from one or more factors that target multiple post-receptor signaling steps, the molecular basis of signal enhancement by chromium most likely extends beyond the insulin receptor. Careful selection of most relevant insulin signal transduction data in terms of plasma membrane and insulin resistance prompted us to ask if membrane changes largely represent a common denominator explaining chromium action. In preliminary studies on the 3T3L1 adipocyte cell culture system, chromium increased the basal and insulin-stimulated level of plasma membrane GLUT4, an intracellular localized glucose transporter. Chromium also was found to concomitantly diminish cholesterol from the plasma membrane. Replenishment of the lost plasma membrane cholesterol reversed the potentiating action of chromium on GLUT4 mobilization to the cell surface. This proposal will extend upon these findings and use an integrated approach to study several (not mutually exclusive) means by which chromium could exert its GLUT4 regulatory action at the cell membrane. First, we will define plasma membrane architectural changes mediating the chromium enhanced glucose transport process; a subset of that work will test if the cholesterol-dependent actin mesh beneath the cell surface is affected by chromium. Second, we will assess if chromium engages a specific subset of GL UT4 signaling molecules. Evidence supports the idea that several insulin and insulin mimetic signaling components reside or accumulate at cholesterol-dependent regions of the plasma membrane. Our postulate is that key GLUT4 effectors intricately rely upon the activity of membrane lipids and/or actin cytoskeleton at the cell surface. Finally, we will test if chromium corrects signal transduction mechanisms disturbed by insulin resistant conditions that target proximal or distal components of the insulin signaling network. These results will be significant, because they are expected to provide new targets for the preventative and therapeutic interventions that will be particularly important to the growing numbers of insulin resistant individuals in this country who display different biochemical signatures but a shared loss in insulin sensitivity.
描述(由申请人提供):在具有里程碑意义的胰岛素发现三十八年后,铬被确定为维持正常葡萄糖耐量所需的独立因素。与肥胖和 2 型糖尿病最显着相关的胰岛素信号传导和对其生物作用的抵抗力的深入研究不同,铬作用的分子基础多年来一直被断断续续地研究。最近的数据与铬通过增强胰岛素受体的活性来增强胰岛素抵抗状态下的胰岛素作用的理论是一致的。然而,鉴于胰岛素作用受损的病因是由一种或多种针对多个受体后信号传导步骤的因素引起的,铬增强信号的分子基础很可能超出了胰岛素受体的范围。在质膜和胰岛素抵抗方面仔细选择最相关的胰岛素信号转导数据促使我们询问膜的变化是否在很大程度上代表了解释铬作用的共同点。在对 3T3L1 脂肪细胞培养系统的初步研究中,铬增加了质膜 GLUT4(一种细胞内局部葡萄糖转运蛋白)的基础水平和胰岛素刺激水平。还发现铬可以同时减少质膜上的胆固醇。补充丢失的质膜胆固醇逆转了铬对 GLUT4 动员到细胞表面的增强作用。该提案将扩展这些发现,并使用综合方法来研究铬可以在细胞膜上发挥其 GLUT4 调节作用的几种(不是相互排斥的)方法。首先,我们将定义介导铬增强葡萄糖转运过程的质膜结构变化;该工作的一部分将测试细胞表面下方的胆固醇依赖性肌动蛋白网是否受到铬的影响。其次,我们将评估铬是否与 GL UT4 信号分子的特定子集结合。有证据支持这样的观点,即几种胰岛素和胰岛素模拟信号成分驻留在或积聚在质膜的胆固醇依赖性区域。我们的假设是关键的 GLUT4 效应器复杂地依赖于细胞表面膜脂和/或肌动蛋白细胞骨架的活性。最后,我们将测试铬是否可以纠正因胰岛素抵抗条件而干扰的信号转导机制,这些机制针对的是胰岛素信号网络的近端或远端组件。这些结果将具有重要意义,因为它们有望为预防和治疗干预措施提供新的目标,这对于该国越来越多的胰岛素抵抗个体尤其重要,这些人表现出不同的生化特征,但胰岛素敏感性都有所丧失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY S ELMENDORF其他文献

JEFFREY S ELMENDORF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY S ELMENDORF', 18)}}的其他基金

Cholesterol Toxicity as a Promising Target for Diabetes Prevention
胆固醇毒性是预防糖尿病的一个有希望的目标
  • 批准号:
    9767799
  • 财政年份:
    2018
  • 资助金额:
    $ 30.79万
  • 项目类别:
Cholesterol Toxicity as a Promising Target for Diabetes Prevention
胆固醇毒性是预防糖尿病的一个有希望的目标
  • 批准号:
    9596420
  • 财政年份:
    2018
  • 资助金额:
    $ 30.79万
  • 项目类别:
Pilot & Feasibility Progam
飞行员
  • 批准号:
    10633149
  • 财政年份:
    2015
  • 资助金额:
    $ 30.79万
  • 项目类别:
Pilot & Feasibility Progam
飞行员
  • 批准号:
    10427468
  • 财政年份:
    2015
  • 资助金额:
    $ 30.79万
  • 项目类别:
Pilot & Feasibility Progam
飞行员
  • 批准号:
    10155473
  • 财政年份:
    2015
  • 资助金额:
    $ 30.79万
  • 项目类别:
Mechanisms of Membrane-Based Insulin Resistance & Therapeutic Reversal Strategies
膜型胰岛素抵抗的机制
  • 批准号:
    8212266
  • 财政年份:
    2009
  • 资助金额:
    $ 30.79万
  • 项目类别:
Mechanisms of Membrane-Based Insulin Resistance & Therapeutic Reversal Strategies
膜型胰岛素抵抗的机制
  • 批准号:
    7566652
  • 财政年份:
    2009
  • 资助金额:
    $ 30.79万
  • 项目类别:
Mechanisms of Membrane-Based Insulin Resistance & Therapeutic Reversal Strategies
膜型胰岛素抵抗的机制
  • 批准号:
    7778871
  • 财政年份:
    2009
  • 资助金额:
    $ 30.79万
  • 项目类别:
Mechanisms of Membrane-Based Insulin Resistance & Therapeutic Reversal Strategies
膜型胰岛素抵抗的机制
  • 批准号:
    8018039
  • 财政年份:
    2009
  • 资助金额:
    $ 30.79万
  • 项目类别:
Mechanisms of Membrane-Based Insulin Resistance & Therapeutic Reversal Strategies
膜型胰岛素抵抗的机制
  • 批准号:
    8000672
  • 财政年份:
    2009
  • 资助金额:
    $ 30.79万
  • 项目类别:

相似国自然基金

相似海外基金

New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
  • 批准号:
    23K16058
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of STING in Cholestatic Liver Injury
STING 在胆汁淤积性肝损伤中的作用
  • 批准号:
    10637131
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
The role of GPR84 signaling during skin repair
GPR84 信号在皮肤修复中的作用
  • 批准号:
    10637039
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Characterization and Optimization of a Nanofiber-Hydrogel Composite for Tissue Remodeling
用于组织重塑的纳米纤维-水凝胶复合材料的表征和优化
  • 批准号:
    10678462
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Neural Mechanisms of Obesity-Induced Hypertension
肥胖引起的高血压的神经机制
  • 批准号:
    10677977
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Lipid storage and utilization in physiology and obesity
生理学和肥胖中的脂质储存和利用
  • 批准号:
    10663760
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Multimodal omics approach to identify health to cardiometabolic disease transitions
多模式组学方法确定健康状况向心脏代谢疾病的转变
  • 批准号:
    10753664
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
  • 批准号:
    10619176
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
The Role of Fat in Osteoarthritis
脂肪在骨关节炎中的作用
  • 批准号:
    10866687
  • 财政年份:
    2023
  • 资助金额:
    $ 30.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了